Featured Research

from universities, journals, and other organizations

After resection, common treatment of pancreatic cancer as effective as chemotherapy drug dose, study suggests

Date:
September 7, 2010
Source:
JAMA and Archives Journals
Summary:
Use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who received fluorouracil and folinic acid, another treatment regimen that has shown effectiveness, according to a new study.

Use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who received fluorouracil and folinic acid, another treatment regimen that has shown effectiveness, according to a study in the September 8 issue of JAMA.

Related Articles


"Pancreatic cancer is one of the major causes of cancer death globally, with a 5-year survival rate of less than 5 percent. The outlook for those patients who can undergo surgical resection is better, and in specialized centers, resection rates greater than 15 percent can be achieved. Although surgery cannot guarantee a cure, the 5-year survival does improve to around 10 percent following resection. There is a clear need to improve long-term survival in these patients," the authors write.

John P. Neoptolemos, M.D., of the University of Liverpool, U.K., and colleagues conducted a study to determine whether fluorouracil or gemcitabine is superior in terms of overall survival as adjuvant (supplemental) chemotherapy treatment following resection of pancreatic cancer. The European Study Group for Pancreatic Cancer (ESPAC)-3 trial was conducted in 159 pancreatic cancer centers in Europe, Australasia, Japan, and Canada. Included in ESPAC-3 version 2 (the trial was modified) were 1,088 patients with pancreatic ductal adenocarcinoma who had undergone cancer resection; patients were randomized between July 2000 and January 2007 and underwent at least 2 years of follow-up. Patients received either fluorouracil plus folinic acid (leucovorin, an active metabolite of folic acid, which counteracts some of the toxic effects of some chemotherapy drugs) (n = 551) or gemcitabine (n = 537) for 6 months.

During the trial, 753 patients (69 percent) had died at the time of analysis (388 [70 percent] in the fluorouracil plus folinic acid group and 365 [68 percent] in the gemcitabine group). Median (midpoint) length of follow-up of 335 living patients was 34.2 months, equal across treatment groups. Overall, 282 of patients remaining alive (84 percent) had undergone follow-up for more than 2 years. Median survival for patients treated with fluorouracil plus folinic acid was 23.0 months and for patients treated with gemcitabine was 23.6 months.

Estimates of survival at 12 and 24 months were 78.5 percent and 48.1 percent, respectively, for the fluorouracil plus folinic acid group and 80.1 percent and 49.1 percent for the gemcitabine group. Analysis indicated no statistically significant difference in survival estimates between the treatment groups.

"Seventy-seven patients (14 percent) receiving fluorouracil plus folinic acid had 97 treatment-related serious adverse events, compared with 40 patients (7.5 percent) receiving gemcitabine, who had 52 events. There were no significant differences in either progression-free survival or global quality-of-life scores between the treatment groups," the authors write.

"In conclusion, gemcitabine did not result in improved overall survival compared with fluorouracil plus folinic acid in patients with resected pancreatic cancer."

Editorial: Refinement of Adjuvant Therapy for Pancreatic Cancer

Eileen M. O'Reilly, M.D., of Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, writes in an accompanying editorial that while the results of this study provides important information, there is still much work to be done regarding effective treatments for pancreatic cancer.

"Adjuvant therapy for resected pancreatic adenocarcinoma is now firmly established as offering a modest but real improvement in overall survival at 5 years with about double the number of patients alive compared with no treatment. Much attention has been paid to improving adjuvant clinical trial design, in particular excluding patients who have undergone palliative resections from adjuvant studies and streamlining other eligibility criteria. The ESPAC investigators have significantly contributed to the establishment of standard adjuvant therapy."

"Results from the ongoing European and U.S. studies will further refine practice over the next decade; however, there is much to be done including identification of new and active drugs for treating pancreatic cancer that may be translated into the adjuvant setting. Other directions deserving further evaluation include the role of neoadjuvant or preoperative therapy for patients with resectable pancreatic adenocarcinoma, an approach that offers several theoretical advantages over an adjuvant approach. Even though pancreatic cancer remains one of the most challenging malignancies, the next decade looks incrementally brighter."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal References:

  1. Neoptolemos et al. Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial. JAMA The Journal of the American Medical Association, 2010; 304 (10): 1073 DOI: 10.1001/jama.2010.1275
  2. O'Reilly et al. Refinement of Adjuvant Therapy for Pancreatic Cancer. JAMA The Journal of the American Medical Association, 2010; 304 (10): 1124 DOI: 10.1001/jama.2010.1302

Cite This Page:

JAMA and Archives Journals. "After resection, common treatment of pancreatic cancer as effective as chemotherapy drug dose, study suggests." ScienceDaily. ScienceDaily, 7 September 2010. <www.sciencedaily.com/releases/2010/09/100907163329.htm>.
JAMA and Archives Journals. (2010, September 7). After resection, common treatment of pancreatic cancer as effective as chemotherapy drug dose, study suggests. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2010/09/100907163329.htm
JAMA and Archives Journals. "After resection, common treatment of pancreatic cancer as effective as chemotherapy drug dose, study suggests." ScienceDaily. www.sciencedaily.com/releases/2010/09/100907163329.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins